← All trials
NCT04522323
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 5, 2020
- Primary completion
- Jun 16, 2023
- Completion date
- Jun 16, 2023
- First posted
- Aug 21, 2020
- Last posted
- Dec 16, 2020
- Enrollment
- 77
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- MedImmuneLead sponsor
- AstraZenecaStudy director
- AstraZenecaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.